Most Recent Articles by Sony Salzman
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?